The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Utility of circulating tumor DNA in the clinical management of patients with BRAFV600E metastatic colorectal cancer.
 
Van K. Morris
Honoraria - Projects in Knowledge
Consulting or Advisory Role - Array Biopharma; Incyte; SERVIER
Research Funding - Array BioPharma (Inst); Boehringer Ingelheim; Bristol-Myers Squibb (Inst); EMD Serono (Inst)
 
Kanwal Pratap Singh Raghav
Consulting or Advisory Role - AstraZeneca; Bayer; Daiichi Sankyo; Eisai
 
Arvind Dasari
Consulting or Advisory Role - Advanced Accelerator Applications; Ipsen; Lexicon; Novartis; Voluntis
Research Funding - Eisai; Guardant Health; Hutchison MediPharma; Ipsen; Merck; Novartis
 
Michael J. Overman
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Gritstone Bio; Janssen; Janssen; MedImmune; Novartis; Pfizer; Pfizer; Promega; Roche/Genentech; Spectrum Pharmaceuticals
Research Funding - Bristol-Myers Squibb; MedImmune; Merck; Roche
 
Bryan K. Kee
Stock and Other Ownership Interests - Medtronic
 
Benny Johnson
No Relationships to Disclose
 
Christine Megerdichian Parseghian
No Relationships to Disclose
 
John Paul Y.C. Shen
Stock and Other Ownership Interests - Agios; Syndax; Syndax
 
Ryan Huey
No Relationships to Disclose
 
Victoria M. Raymond
Employment - Guardant Health
Stock and Other Ownership Interests - Guardant Health; Trovagene
 
Dzifa Yawa Duose
No Relationships to Disclose
 
Rajyalakshmi Luthra
No Relationships to Disclose
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; Oncorena; Presagia
Consulting or Advisory Role - Acuta Capital; Adaptimmune; Alphasights; Amgen; Axiom Biotechnologies; Bayer; Boxer Capital; EcoR1 Capital; Gerson Lehrman Group; GroupH; Guidepoint Global; Infinity Pharmaceuticals; Medscape; Merrimack; Numab; Pfizer; PrimE Oncology; Seagen; Takeda; Tavistock Life Sciences; Trieza Therapeutics; WebMD
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Aldai Norte (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Daiichi Sankyo (Inst); Fate Therapeutics (Inst); Genentech (Inst); Infinity Pharmaceuticals (Inst); Kite, a Gilead company (Inst); Kura Oncology (Inst); MedImmune (Inst); Molecular Templates (Inst); National Cancer Institute (Inst); Novartis (Inst); Numab (Inst); Pfizer (Inst); Seagen (Inst); Shattuck Labs (Inst); TCR2 Therapeutics (Inst); TP Therapeutics (Inst); Turning Point Therapeutics (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - AACR; ASCO; Bayer Schering Pharma; Genmab; Society for Immunotherapy of Cancer
 
Filip Janku
Stock and Other Ownership Interests - Trovagene
Consulting or Advisory Role - Deciphera; Foundation Medicine; Guardant Health; IDEAYA Biosciences; IFM Therapeutics; Immunome; Jazz Pharmaceuticals; Novartis; PureTech; Sequenom; Sotio; Synlogic; Trovagene; Valeant/Dendreon
Research Funding - Agios (Inst); Asana Biosciences (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); Fujifilm (Inst); Genentech (Inst); Novartis (Inst); Piqur (Inst); Plexxikon (Inst); Proximagen (Inst); Roche (Inst); Symphogen (Inst)
Other Relationship - Bio-Rad
 
Scott Kopetz
Stock and Other Ownership Interests - Lutris; MolecularMatch; Navire
Consulting or Advisory Role - Amal Therapeutics; Amgen; AstraZeneca/MedImmune; Bayer Health; Biocartis; Boehringer Ingelheim; Boston Biomedical; Daiichi Sankyo; EMD Serono; EMD Serono; Genentech; HalioDx; Holy Stone Healthcare; Ipsen; Jacobio; Karyopharm Therapeutics; Lilly; Lutris; Merck; Natera; Navire; Novartis; Pfizer; Pierre Fabre; Redx Pharma; Repare Therapeutics; Roche; Symphogen
Research Funding - Amgen (Inst); Array BioPharma (Inst); Biocartis (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Guardant Health (Inst); Lilly (Inst); MedImmune (Inst); Novartis (Inst); Sanofi (Inst)